Since CD72 is a negative regulator of the B-cell receptor (BCR) signaling pathway, activation of the BCR signaling pathway by specific drugs can promote CD72 expression in B-ALL cells through a negative feedback mechanism, thereby providing additional targets for CD72-directed CAR-T therapy [42]. The gene discussed is CD72; the disease is acute lymphoblastic leukemia.